| Q37095708 | 3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H. |
| Q38693747 | A combination HIV reporter virus system for measuring post-entry event efficiency and viral outcome in primary CD4+ T cell subsets |
| Q46060984 | Achieving an AIDS-free world: science and implementation |
| Q36250921 | Activation and lysis of human CD4 cells latently infected with HIV-1 |
| Q90164177 | An analytical pipeline for identifying and mapping the integration sites of HIV and other retroviruses |
| Q38072056 | Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design. |
| Q41924104 | Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults |
| Q33846203 | Bacterial DNA Protects Monocytic Cells against HIV-Vpr-Induced Mitochondrial Membrane Depolarization. |
| Q33924824 | Behavioral Decision Research Intervention Reduces Risky Sexual Behavior |
| Q34583552 | Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir |
| Q36883462 | Cell-cell contact viral transfer contributes to HIV infection and persistence in astrocytes |
| Q38078562 | Cellular and molecular mechanisms involved in the establishment of HIV-1 latency |
| Q50126703 | Cellular and molecular mechanisms of HIV-1 integration targeting |
| Q47548818 | Characterization of Nanodiamond-based anti-HIV drug Delivery to the Brain. |
| Q37271140 | Characterization of novel inhibitors of HIV-1 replication that function via alteration of viral RNA processing and rev function |
| Q41897622 | Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5 |
| Q40427938 | Combining Cell and Gene Therapy in an Effort to Eradicate HIV. |
| Q43564279 | Comparative Analysis of Tat-Dependent and Tat-Deficient Natural Lentiviruses |
| Q36485204 | Crystallographic Identification of Lipid as an Integral Component of the Epitope of HIV Broadly Neutralizing Antibody 4E10. |
| Q39301512 | Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies |
| Q55286937 | Cytotoxicity assessment, inflammatory properties, and cellular uptake of Neutraplex lipid-based nanoparticles in THP-1 monocyte-derived macrophages. |
| Q45074789 | Dendritic cell targeted HIV-1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells |
| Q33879481 | Disclosure and Experienced Social Support are not Related to Anxiety or Depression in a German HIV Patient Cohort |
| Q41040182 | Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands. |
| Q47585647 | Early HIV infection among persons referred for malaria parasite testing in Nigeria |
| Q55255033 | EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment. |
| Q37258308 | Effect of combination antiretroviral therapy on Chinese rhesus macaques of simian immunodeficiency virus infection |
| Q36253793 | Effect of the Latent Reservoir on the Evolution of HIV at the Within- and Between-Host Levels |
| Q38119498 | Feline immunodeficiency virus latency. |
| Q37348748 | Gene-expression reversal of lncRNAs and associated mRNAs expression in active vs latent HIV infection |
| Q28543775 | Genotypes and transmitted drug resistance among treatment-naive HIV-1-infected patients in a northwestern province, China: trends from 2003 to 2013 |
| Q90555402 | Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals |
| Q27681313 | HIV Cell-to-Cell Spread Results in Earlier Onset of Viral Gene Expression by Multiple Infections per Cell |
| Q38210557 | HIV vaccines: a brief overview. |
| Q38204866 | HIV-1 latency: an update of molecular mechanisms and therapeutic strategies |
| Q37716750 | Host Immune Responses in HIV-1 Infection: The Emerging Pathogenic Role of Siglecs and Their Clinical Correlates. |
| Q34370314 | Immune clearance of highly pathogenic SIV infection |
| Q37678580 | Immune surveillance and response to JC virus infection and PML. |
| Q37098356 | Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients? |
| Q39328033 | Impact of antiretroviral therapy duration and intensification on isolated shedding of HIV-1 RNA in semen |
| Q37999623 | Innate immunity in the control of HIV/AIDS: recent advances and open questions |
| Q38071699 | Is specific HIV eradication from the brain possible or needed? |
| Q27339956 | Large Variations in HIV-1 Viral Load Explained by Shifting-Mosaic Metapopulation Dynamics |
| Q41760939 | Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses |
| Q30373903 | Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis. |
| Q40419472 | Modulation of the splicing regulatory function of SRSF10 by a novel compound that impairs HIV-1 replication |
| Q90356724 | Nucleolar protein NOP2/NSUN1 suppresses HIV-1 transcription and promotes viral latency by competing with Tat for TAR binding and methylation |
| Q30384172 | Pandemic Influenza A (H1N1) Virus Infection Increases Apoptosis and HIV-1 Replication in HIV-1 Infected Jurkat Cells. |
| Q38182590 | Pathogenesis of HIV Infection |
| Q36736667 | Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy. |
| Q40401650 | Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects |
| Q35055187 | Platelets and erythrocyte-bound platelets bind infectious HIV-1 in plasma of chronically infected patients |
| Q26797870 | Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus |
| Q91947425 | Post-traumatic Stress Disorder, Cocaine Use, and HIV Persistence |
| Q36727960 | Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors |
| Q36111190 | Preparation, characterization, and safety evaluation of poly(lactide-co-glycolide) nanoparticles for protein delivery into macrophages |
| Q38171839 | Progress in understanding oral health and HIV/AIDS. |
| Q92538321 | Quantification of Viral RNA and DNA Positive Cells in Tissues From Simian Immunodeficiency Virus/Simian Human Immunodeficiency Virus Infected Controller and Progressor Rhesus Macaques |
| Q34025414 | RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. |
| Q37538638 | Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects |
| Q37098218 | Recruitment and ethical considerations in HIV cure trials requiring treatment interruption |
| Q44950359 | Roadblocks to translational challenges on viral pathogenesis |
| Q58792426 | Sanger and Next Generation Sequencing Approaches to Evaluate HIV-1 Virus in Blood Compartments |
| Q36125264 | Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch |
| Q58575909 | The Ambiguous Roles of Extracellular Vesicles in HIV Replication and Pathogenesis |
| Q53063059 | The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2. |
| Q30431054 | The HIV-1 pandemic: does the selective sweep in chimpanzees mirror humankind's future? |
| Q38602400 | The Y chromosome: a blueprint for men's health? |
| Q33586581 | The detection and management of early HIV infection: a clinical and public health emergency |
| Q36505647 | The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy |
| Q38088556 | The search for an HIV cure: tackling latent infection |
| Q39169410 | Therapeutic HIV vaccines: prior setbacks, current advances, and future prospects |
| Q36589574 | Toward the development of a single-round infection assay based on EGFP reporting for anti-HIV-1 drug discovery |
| Q41682866 | UCLA1 aptamer inhibition of human immunodeficiency virus type 1 subtype C primary isolates in macrophages and selection of resistance |
| Q28077662 | Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research |
| Q36987230 | What Integration Sites Tell Us about HIV Persistence |
| Q35586914 | Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques |
| Q40609511 | Will LEDGIN molecules be able to play a role in a cure for HIV infection? |
| Q47564080 | eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients |